This grant is for establishing a Coordinating and Data Management Center (CDMC) to support the Translational and Basic Science Research in Early Lesions (TBEL) program. The TBEL program aims to integrate basic and translational cancer research, examining the direct causal relationships of early lesions, their microenvironment, and host-systemic factors in tumor initiation and progression. The ultimate goal is to understand the biological mechanisms driving or restraining precancers and early cancers, facilitating biology-backed precision prevention approaches. The CDMC’s responsibilities include coordinating consortium-wide activities, providing statistical and computational analysis support, and establishing a program data hub for data capture, curation, and management.
Opportunity ID: 335507
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-21-055 |
| Funding Opportunity Title: | Translational and Basic Science Research in Early Lesions (TBEL) Coordinating and Data Management Center (U24 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 31, 2021 |
| Last Updated Date: | Aug 31, 2021 |
| Original Closing Date for Applications: | Nov 02, 2021 |
| Current Closing Date for Applications: | Nov 02, 2021 |
| Archive Date: | Dec 08, 2021 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses State governments City or township governments County governments Special district governments Independent school districts Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The TBEL program aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment, and host-systemic factors as co-organizers of tumor initiation (or suppression) and malignant progression. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. The responsibilities of the CDMC will be to (1) coordinate consortium-wide meetings and conferences, and cross-consortium collaborative activities; (2) provide statistical and computational analysis support; and (3) establish program data hub for data capture, curation and management, and protocol development and registration. The other scientific unit of the TBEL program will comprise the U54 Centers, which will be structured to efficiently bridge gaps between basic and translational research on early lesions and their microenvironments. This Notice is being provided to allow potential applicants sufficient time to develop a responsive TBEL Coordinating and Data Management Center application. The FOA is expected to be published in May 2021 with an anticipated application due date in October 2021. Details of the planned pre-application webinar will be announced in the Guide after publication of the FOA. The companion notice for the TBEL U54 Centers is: NOT-CA-21-XXX. The FOA will not be restricted to specific early lesion/cancer type(s). |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-055.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00268774 | Oct 02, 2021 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00269610 | Oct 27, 2021 | Nov 02, 2021 | View |
Package 1
Mandatory forms
335507 RR_SF424_2_0-2.0.pdf
335507 PHS398_CoverPageSupplement_5_0-5.0.pdf
335507 RR_OtherProjectInfo_1_4-1.4.pdf
335507 PerformanceSite_2_0-2.0.pdf
335507 RR_KeyPersonExpanded_2_0-2.0.pdf
335507 RR_Budget_1_4-1.4.pdf
335507 PHS398_ResearchPlan_4_0-4.0.pdf
335507 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
335507 RR_SubawardBudget30_1_4-1.4.pdf
335507 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
335507 RR_SF424_5_0-5.0.pdf
335507 PHS398_CoverPageSupplement_5_0-5.0.pdf
335507 RR_OtherProjectInfo_1_4-1.4.pdf
335507 PerformanceSite_4_0-4.0.pdf
335507 RR_KeyPersonExpanded_4_0-4.0.pdf
335507 RR_Budget_3_0-3.0.pdf
335507 PHS398_ResearchPlan_4_0-4.0.pdf
335507 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335507 RR_SubawardBudget30_3_0-3.0.pdf
335507 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
